News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer.
As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments in cancer drug discovery this week. Most notably, a 20-year mystery regarding the ‘dark matter’ of the genome has been solved and researchers have announced preclinical success in treating ovarian cancer with CAR-T therapy.
The top stories:
The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.
A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs.
Cancer Research Horizons and Singapore’s Experimental Drug Development Centre (EDDC) have announced a five-year strategic partnership to accelerate the translation of cancer research into improved treatments for cancer patients.
CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer. The study authors hope that the discovery will pave the way for a clinical trial to see how effective the treatment is for women with the disease.
SiSaf is to collaborate with the University of Leipzig, Germany, to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.